Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RELA | Q04206 | 4/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | REN | P00797 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.33 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.33 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.33 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.33 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.33 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.33 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6565161 | 0.89 | PSEN1 (0.35) | RELACA1CA2CA12CA7 | |
| SCHEMBL628815 | 0.80 | CYP1A2 (0.44) | CA2CYP1A2RENEPHX1ALDH1A1 | |
| SCHEMBL8394615 | 0.79 | CYP1A2 (0.42) | CA1CA2CA12CA7CA14 | |
| SCHEMBL7042054 | 0.78 | RELA (0.55) | RELACA1CA2CA12CA7 | |
| SCHEMBL5689484 | 0.78 | CA1 (0.61) | RELACA1CA2CA12CA7 | |
| SCHEMBL7039396 | 0.78 | RELA (0.55) | RELACA1CA2CA12CA7 | |
| SCHEMBL7109328 | 0.78 | RELA (0.55) | RELACA1CA2CA12CA7 | |
| SCHEMBL4071690 | 0.76 | POLB (0.40) | CA1CA2CA12CA7CA14 | |
| SCHEMBL1753871 | 0.76 | RELA (0.58) | RELACA1CA2CA12CA7 | |
| SCHEMBL7688181 | 0.74 | RELA (0.61) | RELACA1CA2CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1296945-B1 | SULFONAMIDE DERIVATIVES | LILLY CO ELI (US) | 2004-08-04 | — | — | EP | disclosed |
| US-6703425-B2 | ADMINISTERING GLUTAMATE RECEPTOR POTENTIATOR TO TREAT PSYCHOLOGICAL AND NERVOUS SYSTEM DISORDERS | ELI LILLY AND COMPANY | 2004-03-09 | — | — | US | disclosed |
| US-20030229102-A1 | Sulfonamide derivatives | ELI LILLY AND COMPANY | 2003-12-11 | — | — | US | disclosed |
| EP-1296945-A1 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2003-04-02 | — | — | EP | disclosed |
| WO-2001096289-A1 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229102-A1 | Sulfonamide derivatives | GRIN1, GRIN2A, SLC1A2 | RELA 2481/4885CA1 307/4885CA2 867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.